Tivozanib-d6

Tivozanib-d6 (AV-951-d6) is deuterium labeled Tivozanib. Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR) -1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy[1][2].

Product Specifications

CAS Number

[1714998-87-4]

Product Name Alternative

AV-951-d6; KRN951-d6

UNSPSC

12352005

Target

Isotope-Labeled Compounds; VEGFR

Type

Isotope-Labeled Compounds

Related Pathways

Others; Protein Tyrosine Kinase/RTK

Field of Research

Cancer

Smiles

O=C(NC1=NOC(C)=C1)NC2=CC=C(OC3=CC=NC4=CC(OC([2H])([2H])[2H])=C(OC([2H])([2H])[2H])C=C34)C=C2Cl

Molecular Formula

C22H13D6ClN4O5

Molecular Weight

460.90

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Nakamura K, et al., KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006 Sep 15;66 (18) :9134-42.